IDMoS aims for £2m in share placing:
This article was originally published in Clinica
Executive Summary
IDMoS (Dundee, Scotland), a specialist in producing disease detection and monitoring technology, is expecting to raise £2m ($3.98m) before expenses through the conditional placing of around 5.25 million shares at 35p per share. The financing is conditional, on admission of the shares trading on the UK AIM stock exchange and the approval by shareholders of certain resolutions. The company intends to use the proceeds for the launch of its dental decay detection and monitoring products, the Caries Detection Device (CDD) and its Caries Management Support System (CMSS), which are expected to go on sale in the US and European markets later this year.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.